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TET2 is a methylcytosine dioxygenase that is frequently mutated in myeloid malignancies, notably myelodysplasia and acute
myeloid leukemia. TET2 catalyses the conversion of 5󸀠-methylcytosine to 5󸀠-hydroxymethylcytosine within DNA and has been
implicated in the process of genomic demethylation. However, the mechanism by which TET2 loss of function results in
hematopoietic dysplasia and leukemogenesis is poorly understood. Here, we show that TET2 is expressed in undifferentiated
embryonic stem cells and that its knockdown results in reduction of 5󸀠-hydroxymethylcytosine in genomic DNA. We also present
DNA methylation data from bone marrow samples obtained from patients with TET2-mutated myelodysplasia. Based on these
findings, we sought to identify the role of TET2 in regulating pluripotency and differentiation. We show that overexpression
of TET2 in a stably integrated transgene leads to increased alkaline phosphatase expression in differentiating ES cells and
impaired differentiation in methylcellulose culture. We speculate that this effect is due to TET2-mediated expression of stem
cell genes in ES cells via hydroxylation of 5󸀠-methylcytosines at key promoter sequences within genomic DNA. This leads to
relative hypomethylation of gene promoters as 5󸀠-hydroxymethylcytosine is not a substrate for DNMT1-mediated maintenance
methylation.We sought to test this hypothesis by cotransfecting the TET2 gene with methylated reporter genes.The results of these
experiments are presented.
1. Introduction
1.1. TETGenes, Function, and Background. The family ofTET
(ten-eleven translocations) genes comprise three members,
TET1, TET2, and TET3, each with high level of homology
to one another. TET2, at locus 4q24, has three distinct
variant forms from alternative splicing, each of which pos-
sesses 2-oxoglutarate- (2OG-) Fe(II) dependent oxygenase
activity that is dependent on 𝛼-ketoglutarate and Fe2+ ion
as cofactors [1, 2]. TET2 acts functionally to catalyse the
base conversion of 5-methylcytosine (5mC) DNA to 5-
hydroxymethyl-cytosine (5hmC) [3–7]. Other 2OG-Fe(II)-
dependent enzymes are common in humans with a broad
spectrum of functions including DNA repair, hypoxia sens-
ing, histone demethylation, fatty-acid metabolism, and col-
lagen stabilization [8]. In recent studies He et al. and Ito et
al. used thin layer chromatography (TLC) and mass spec-
trometry to show that TET2 has further oxidative activity to
convert 5hmC to 5-carboxylcytosine (5caC) in HEK293T cells,
although the other expected intermediate, 5-formylcytosine
(5fC), was only observed in mouse embryonic stem (ES) cells
in the study by Ito et al. [9] and He et al. [10]. 5caC is a
relatively stable base modification and an active demethyla-
tion process was seen involving thymine-DNA-glycosylase
(TDG) base excision repair [10]. Recent evidence suggests
that 5hmC can also be dehydroxymethylated to cytosine by the
de novomethyltransferase proteins DNMT3A and DNMT3B
although this needs to be confirmed by other studies [11].
Thus, TET2 plays a central role in the biology of cytosine
methylation. However, the functional role of TET2 in the cell
and the importance of its product 5hmC to transcriptional
activity of genes remain to be elucidated.
1.2. TET2 in ES Cells and Mutations in MDS/AML. TET2
mutation is enriched amongst cases of myeloid malignancy
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occurring in approximately 12% of acute myeloid leukemia
(AML) cases and up to 58% of mixed myeloproliferative
neoplasms (MPN) and myelodysplastic syndromes (MDS)
[12–14]. Therefore, it is likely that TET2 plays an important
role in regulation of hematopoietic differentiation and may
even serve as a prognostic tool inmyeloidmalignancies. AML
is characterized by enhanced proliferation and impaired
differentiation of myeloid progenitors, resulting in clonal
populations of immature hematologic blasts. Furthermore
specific AML subgroups show patterns of dysregulated DNA
methylation patterns, which can be correlated with patient
survival [4]. The majority of TET2 mutations recorded in
patients with myeloid malignancy are within regions critical
for enzymatic activity suggesting they are loss of function
mutations and hence TET2 is seen to be having a tumour
suppressor role [1, 3].
The clinical outcome of patients with a mutation in TET2
remains contentious. In AML patients, one study found a
decreased survival rate in TET2 mutants when compared
to a wild-type group [15], whereas another study found no
significant impact of mutation status on clinical outcome,
but mutation was strongly associated to a mutation in the
NPM1 gene, which is also implicated in AML [16, 17]. InMDS
patients the 5-year survival rate was 76.9% for TET2mutants
against 18.3% for wild-type, indicating amutation as amarker
for good prognosis [18]. Additionally, Smith et al. could
find no prognostic significance for TET2 mutation when
patients were clustered into WHO subtypes, scored using
the International Prognostic Scoring System, or grouped into
cytogenic status or progression to AML [19].
The isocitrate dehydrogenase enzyme IDH1 and its mito-
chondrial homologue IDH2 are responsible for converting
isocitrate to 𝛼-ketoglutarate in the Krebs/TCA cycle. Het-
erozygous gain of function mutations of IDH1 and IDH2 has
been shown to convert isocitrate into 2-hydroxyglutarate (2-
HG) which competes with 𝛼-ketoglutarate to inhibit TET
activity [4]. Various similarities exist between TET2 mutant
and IDH1/2 mutant phenotypes including increased 5mC in
cultured cells and an increase in progenitor cell numbers
and stem cells markers [4]. These findings provide important
insights into a possible common mechanism of epigenetic
disruption that may lead to AML or precursor diseases such
as MDS.
1.3. Methylcytosine, Hydroxymethylcytosine, and Its Effect on
Promoter Activity. The total 5mC content of the human
genome is 1–3% of all cytosine bases [3, 20–22] occurring
almost exclusively at CpG dinucleotides. Clusters of CpG
sites occurring at higher than expected frequency within
genomic regions are termed CpG islands (CGIs) which are
generally hypomethylated within cells. Around 65% of CGIs
localise around the point of gene promoter regions including
all constitutively expressed genes [23]. Aberrant methylation
of CGIs leads to stable transcriptional repression and is
thought to be important in silencing tumour suppressor
genes in some conditions such as MDS. CGI methylation at
promoter regions upstream of genes has the greatest effect on
transcription via prevention of elongation of the transcript
[20]. Some evidence suggest that CGI methylation within
exonic regions of genes is permissive of transcription and
does not block initiation or elongation [24]. The recent
discovery of cytosine hydroxymethylation raises the possi-
bility that methylation at CGIs can be reversed via active
cytosine demethylation involving TET proteins leading to the
reactivation of transcriptionally silenced promoters [9, 10].
Furthermore new evidence on induced pluripotent stem cells
(iPSCs) suggests that the 5hmC base modification not only is
an intermediate within cytosine demethylation, but acts as
an epigenetic mark in itself, possibly aiding in recruitment
of factors that promote chromatin remodeling [25, 26].
We show here that levels of 5hmC are reduced by TET2
knockdown in ES cells and in TET2 mutated MDS bone
marrow samples. We investigated the phenotypic effects of
TET2 overexpression on differentiation of murine ES cells
using stable transfectants. Finally, using reported genes, we
show that transient overexpression of TET2 has no significant
effect on the transcriptional activity ofmethylated promoters.
2. Results
2.1. Differentiation of ES Cells Leads to Decreased 5ℎ𝑚C. We
sought to investigate the levels of 5mC and 5hmC in undif-
ferentiated murine ES cells using HPLC mass spectrometry.
We found levels of 7.5% for 5mC and 0.15% for 5hmC relative
to guanosine bases demonstrating that 5mC is present in
ES cells at approximately 50-fold greater levels than 5hmC
(Figure 1(a)).
Next we sought to investigate what happens to levels of
5
hmCduring induction of differentiation.We compared levels
of 5hmC in undifferentiated ES cells grown in the presence of
leukemia inhibitory factor (LIF) and in differentiated cells 5
days post-LIF withdrawal (Figure 1(b)). We found that levels
of 5hmC fall by approximately 50% from 0.155% to 0.072%
relative to guanosine bases upon differentiation. This result
suggests that LIF withdrawal induces downregulation of one
or more of the TET family genes leading to a reduction in
conversion of 5mC to 5hmC.
2.2. Knockdown of TET2 in ES Cells Causes Reduced Lev-
els of 5ℎ𝑚C. Based on this finding we performed siRNA
knockdown experiments of the TET2 gene. Using two dif-
ferent gene-specific siRNA oligos in triplicate knockdown
experiments we measured reductions in 5hmC levels of 5%
and 20%, respectively, compared with a scrambled control
(Figure 1(c)). These results provide evidence that TET2, like
TET1, catalyses the conversion of 5mC to 5hmC.
2.3. Measurement of 5ℎ𝑚C Levels in TET2MutatedMDS/AML
Patient Marrow Samples. Genomic DNA analysis usingmass
spectrometry of five patients with myeloid malignancy failed
to identify a clear association between the TET2 mutational
status and 5hmC levels (Figure 1(d)). Patient samples were
genotyped to identify mutations within the TET2 gene locus;
any patients found to have a mutation were heterozygous
wild-type. While this result is based on a small number of
samples and was not correlated with the size of the malignant
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Figure 1:Hydroxymethylation status in ES cells under differentiation andTET2 knockdown and in patient samples.HPLCmass spectrometry
was used to determine the levels of methylcytosine (5mC) and hydroxymethylcytosine (5hmC) expressed as a percentage of total guanosine
bases. All experiments were in triplicate and averaged, unless otherwise stated. (a) 5󸀠-hydroxymethylcytosine is 0.15% of wild-type ES cells.
Levels of 5hmC were compared to levels of 5mC in undifferentiated E14 ES cells, grown in the presence of LIF to maintain an undifferentiated
state; levels were 0.15% and 7.5%, respectively. (b) 5󸀠-hydroxymethylcytosine levels fall in differentiated ES cells. 5hmC levels dropped by
approximately 50% from 0.15% to 0.076% relative to guanosine bases upon differentiation via the removal of LIF from the growthmedia. 5hmC
levels were determined on day 5 after removal of LIF from the growth medium. (c) Effect of TET2 knockdown on 5󸀠-hydroxymethylcytosine
levels. Small inhibitory RNA (siRNA) knockdown of TET2 using a control scrambled oligonucleotide (wild-type ES), and two specific TET2
oligonucleotides (Oligo 1 and Oligo 2). Oligo 1 showed no significant knockdown of 5hmC levels compared to the control, whereas Oligo 2
showed reduced levels of 5hmC upon HPLCmass spectrometric analysis of around 18% compared to control. (d) Bone marrow samples from
patients with myelodysplasia. Marrow samples from myelodysplastic syndrome (MDS) patients were analysed with the mass spectrometer
for 5hmC status. Patients were genotyped for mutations in the TET2 gene locus and any mutants were found to be heterozygous for the TET2
gene.
clone or the nature of the genetic mutation, it nonetheless
shows that global deficiency of 5hmC is not sufficient on
its own to cause disease. However, it does not preclude the
possibility that localised loss of 5hmC at specific gene sites has
occurred in TET2mutated disease.
2.4. Stable Transfection of Murine ES Cells with a TET2-
Containing Plasmid Vector Leads to Slight Increased 5ℎ𝑚C
Level Immunostaining. E14murine ES cells were stably trans-
fected with TET2-pCDNA3 plasmid vector (TET2 stable
transfects) or empty pCDNA3 plasmid as a control (EV
stable transfects) in triplicate. Selection in G418 antibiotic
confirmed the presence of the incorporated plasmid DNA
and surviving colonies were grown to confluency. Figure 2
shows that TET2 was present to a relatively similar degree
in both EV and TET2 stable transfects and was strongly
associated to the nuclear region of cells. 5hmC levels were
slightly raised in TET2 stable transfects.
2.5. Stable Transfection of TET2-pCDNA3 Vector Reduces ES
Cellular Differentiation as Observed by Leukocyte Alkaline
Phosphatase Analysis. A differentiation assay was conducted
by removing LIF from the media and relative differenti-
ation measured using alkaline phosphatase (AP) analysis,
where each colony is attributed to a leukocyte AP analysis
(LAPA) score. Reducing alkaline phosphatase activity is an
indicator of increasing differentiation. LAPA scoring of 7
day differentiating cells revealed colonies from the TET2-
pCDNA3 condition having an average LAPA score of 0.9
compared to 0.45 for the control group, showing that the
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Figure 2: Stable transfection ofmurine ES cells with a pCDNA-TET2plasmid vector leads to slight increased immunostaining for 5hmC. Stably
transfected E14 murine ES cells were grown to confluency and analysed by immunocytochemistry for 5hmC, TET2, and 4󸀠,6-diamidino-2-
phenylindole (DAPI) as a nuclear-identifying control. Empty vector (EV) stable transfect cells are shown in (a) and TET2 stable transfect cells
are shown in (b).
TET2-pCDNA3 transfect colonies were on average 50% less
differentiated than the control transfect colonies at the time
of analysis (Figure 3(a)). A total of 262 colonies were analysed
for AP activity across the two conditions. Figure 3(b) shows
typical colonies observed at 7 days of differentiation post-LIF
withdrawal and stained for AP activity.
2.6. Stable Transfection of Murine ES Cells with a TET2-
Containing Plasmid Vector Leads to a Slightly Reduced Ability
to Differentiate under Methylcellulose + G-CSF. Following
this we conducted a further differentiation experiment using
methylcellulose with granulocyte-colony stimulating factor
(G-CSF). At 22 days under MethoCult + G-CSF differenti-
ation cells showed a slight difference in extent of differen-
tiation, with an indication of a reduction in the percentage
of cell colony differentiation seen with the TET2-pCDNA3
vector transfects compared to controls (Figure 4(a)). A total
of 412 colonies were scored based on the MethoCult GF
H4034 protocol and observed under a light microscope
across triplicate experiments of both TET2-pCDNA3 vector
and pCDNA3 control stable transfects, respectively. Typical
colonies observed are illustrated in Figure 4(b).
2.7. Murine ES Cell Differentiation Fails to Overcome Methy-
lation Induced Silencing. pRL (Renilla) and pGL3 (Firefly)
Luciferase reporter plasmids were then used to determine the
ability of E14 cells to demethylate a previously methylated
reporter plasmid. Transient transfections were carried out
using methylated or unmethylated pRL reporter plasmid in
differentiating (−LIF) or undifferentiating (+LIF) conditions
and relative luminescence was compared to the secondary
pGL3 reporter that was not methylated (Figure 5(a)). No
significant difference was seen between the −LIF and +LIF
conditions; however, the methylated pRL condition leads to
a significant reduction (of around 96%) in relative Renilla
luminescence compared to Firefly. This shows the methy-
lation had successfully silenced the reporter, by reducing
the cells ability to express the Renilla protein, but upon
differentiation there was no difference in the cells ability to
demethylate and hence reexpress the reporter gene.
2.8. TET2 Fails to Overcome Silencing of a Methylated
Luciferase GeneWhen Cotransfected into HEK Cells. In order
to determine if the concentration of TET2 protein within the
cell impacts DNA methylation, transient transfection exper-
iments were performed on HEK293T cells using the pRL
reporter plasmid (either methylated or unmethylated) plus
differing concentrations of the TET2-pCDNA3 plasmid con-
struct (Figure 5(b)). The unmethylated pRL plasmid control
showed high luminescence in comparison with methylated
pRL with relative expression reduced by >98%. However,
increasing amounts of TET2-pCDNA3plasmid cotransfected
with the pRL reporter failed to demonstrate any significant
difference in Renilla expression levels.
3. Discussion
Our findings reveal that ES cell differentiation induced by
LIF-removal is associated with a 50% reduction in levels of
hydroxymethylcytosine that is likely to be due to downregu-
lation of TET genes. We also demonstrate that knockdown
of TET2 in ES cells leads to reduced levels of 5hmC even
in the presence of LIF consistent with the finding of others
suggesting that TET2 normally converts 5mC to 5hmC [3–
7]. Our observations suggest that TET2 gene expression is
important for maintenance of ES cell pluripotency although
themechanismwhereby this occurs is not clear.We speculate
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Figure 3: Alkaline phosphatase analysis of stably transfected ES cells at 7 days post-LIF removal. Once at confluency stably transfected
pCDNA3 and TET2-pCDNA3 E14 ES cells were plated at 1000 cells per plate on gelatin coated 10 cm tissue culture plates in triplicate. 72 hours
after plating LIF was removed from the media and colonies were left to grow for a further 7 days. Analysis of alkaline phosphatase activity
was conducted using the Alkaline Phosphatase Leukocyte kit (Sigma-Aldrich) and each colony was given a leukocyte alkaline phosphatase
(LAPA) score. (a) Average LAPA scores of stably transfected ES cells at 7 days post-LIF removal. A total of 159 colonies were analysed for
the TET2-pCDNA3 condition and 128 for the pCDNA3 condition. The LAPA score for TET2-pCDNA3 was 0.9 (inverse was 1.07), whereas
pCDNA3 stable transfects had an average LAPA score of 0.45 (inverse was 2.22), showing that the TET2-pCDNA3 colonies were 50% less
differentiated than the control colonies. (b) shows colonies at 7 days post-LIF removal that have been stained for alkaline phosphatase (AP)
activity.
that TET proteins prevent silencing of stem cell genes by
maintaining promoters in a hypomethylated state.Thismight
also explain why loss of function of TET2 contributes to
myeloidmalignancies such asMDS andAMLdue to silencing
of tumour suppressor genes via aberrant promoter methy-
lation. In support of this possibility, mutations of IDH1 and
IDH2 also occur in myeloid malignancies where neomorphic
activity of the enzyme results in aberrant generation of 2-
hydroxyglutarate, which inhibits the 2-oxoglutarate depen-
dent conversion of 5mC to 5hmC by TET2 [4, 7].
We studied the association between the TET2mutational
status and 5hmC levels in bonemarrow samples obtained from
patients with myelodysplasia. We found no clear association
between 5hmC levels and TET2 mutational status although
importantly the IDH1/2 mutational status of these samples
was not known. Whilst our analysis of patient samples here
was limited due to small numbers, we note with interest that
other investigators have indeed found that TET2 and IDH1/2
mutated bone marrow samples typically have reduced levels
of 5hmC compared with nonmutated samples from patients
with MDS or AML [4].
We sought next to test the hypothesis that TET2 expres-
sion promotes ES cell pluripotency. We find that ES cells
carrying a stably integrated TET2 transgene expressed more
alkaline phosphatase following LIF removal than control
ES cells carrying the empty vector suggesting that aberrant
expression ofTET2may impair normal ES cell differentiation.
Consistent with this result, we find that ES cells carrying
theTET2 transgene yieldedmore undifferentiated colonies in
methylcellulose culture than did ES cells carrying the empty
6 Bone Marrow Research
50
55
60
65
70
75
80
85
90
TET2 stable transfects EV stable transfects
C
ol
on
y 
di
ffe
re
nt
ia
tio
n 
(%
)
Stable transfect colonies differentiated at 21 days
after plating methylcellulose + G-CSF
(a)
EV stable transfectsTET2 stable transfects
(b)
Figure 4: Methylcellulose differentiation of stably transfected ES cells in the presence of hematopoietic cytokines. E14 ES cells were stably
transfected as described and grown to confluency. Triplicate 10 cm gelatin coated tissue culture plates containing 4000 cells each were plated
of both the TET2-pCDNA3 (TET2 stable transfect) and pCDNA3 control (EV stable transfect). Cells were differentiated using MethoCult
GF H4034 (Stem Cell Technologies), a combination of methylcellulose and granulocyte-colony stimulating factor (G-CSF) in the media and
colonies analysed according to the manufacturer’s instructions at day 22 after plating for differentiation. A total of 229 colonies were classified
in the TET2 stable transfect condition and 173 colonies for the EV stable transfect condition. (a) Relative differentiation levels of TET2 stable
transfects and EV stable transfects at 22 days under methylcellulose condition. TET2 stable transfects were on average 8% less differentiated
at the time of analysis. (b) Photomicrographs of embryoid bodies derived from stably transfected ES cells.
vector suggesting again that TET2 expression promotes a
pluripotent ES cell state.
Based on our findings we hypothesised that TET2 func-
tions by maintaining gene promoters in a hypomethylated
state and that this is important for ES cell pluripotency. Our
results failed to demonstrate any significant effect of TET2
cotransfection on luciferase expression suggesting that the
TET2 enzyme is unable to reactivate gene silencing due to
promoter methylation. However, we were unable to confirm
expression of the TET2 transgene over and above the endoge-
nous gene. Moreover, TET2-mediated “demethylation” may
occur via passive loss of methylcytosines during cell division
rather than active demethylation of methylated promoters
[23]. Transfection experiments in undifferentiated and differ-
entiated ES cells once again failed to demonstrate differential
expression of the luciferase reporter genes according to the
methylated state of their promoters. Hence, we conclude that
TET2 does not directly affect transcriptional activity of genes
at methylated promoters. However, it remains distinctly pos-
sible that TET2 functions to maintain unmethylated genes in
an active state by maintenance of promoter hypomethylation
via hydroxylation of methylcytosines leading to passive loss.
If so, then we speculate that this action may be important for
the role of TET2 in ES cell pluripotency and myeloid tumour
suppression.
4. Materials and Methods
4.1. Cell Culture. Human embryonic kidney (HEK)
293T cells were cultured in Dulbecco’s modified eagle
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Renilla expression
Figure 5: (a) Expression of methylated reporter plasmids is identical in differentiated and undifferentiated ES cells. A Dual Luciferase
Reporter Assay (Promega) was modified to determine if E14 murine ES cells undergoing differentiation were more able to demethylate
(unsilenced) a reporter gene plasmid. Methylation of the pRL reporter by SssI methylase (Promega M0226S) showed optimal gene silencing,
and relative expression of the Renilla Luciferase was compared to the unmodified pGL3 plasmid expression of Firefly Luciferase via a
luminometer. E14 cells were plated at 1 × 105 cells per well in a 24-well plate in triplicate experiments and induced to differentiation on
day 1 posttransfection by removal of leukemia inhibitory factor (LIF), and transient transfection of both the pGL3 and methylated pRL
was conducted using the Lipofectamine LTX (Invitrogen) reagent as per the manufacturer’s instructions on day 5 after plating. Analysis
of Renilla and Firefly expression was conducted on day 6. Transient transfection of unmodified pRL and pGL3 was used as a control. (a)
shows that although methylation clearly had a significant silencing effect on pRL, there was no significant difference seen between the −LIF
(differentiating) or +LIF (undifferentiated) conditions on relative expression of pRL. (b) TET2 is unable to overcome silenced expression of
a cotransfected methylated Renilla plasmid. Human embryonic kidney (HEK) 293T cells were plated at 3 × 104 cells per well in a 24-well
plate in triplicate and transiently transfected using the Lipofectamine LTX (Invitrogen) reagent as per the manufacturer’s instruction on
day 1 after plating with both Dual Luciferase reporter plasmids and a TET2-pCDNA3 construct plasmid. Control experiments were run in
parallel with either no pRLmethylation, no pCDNA-TET2 cotransfect, or a pCDNA3 (empty vector) cotransfect. Dual Luciferase experiments
were modified by methylation of the pRL reporter by SssI methylase (Promega M0226S), which showed optimal gene silencing, and relative
expression of the Renilla Luciferase was compared to the unmodified pGL3 plasmid expression of Firefly Luciferase via a luminometer.
Experiments were conducted in triplicate and averaged. Cotransfection of a TET2-pCDNA3 plasmid vector at varying concentrations with
the Dual Luciferase plasmids does not lead to changes in the unsilencing (demethylation) of the methylated reporter. Control 1 shows again
that unmethylated pRL plasmid has much higher expression levels than the methylated form. There was no dose response, even when 2𝜇g
of TET2-pCDNA3 plasmid DNA was added to each well, and there was no difference in Renilla expression between controls 2 and 3 and
between those cotransfections that contained the TET2-pCDNA3 plasmid.
medium (DMEM) supplemented with 10% fetal calf serum,
100 𝜇g/mL penicillin, 100 𝜇g/mL streptomycin, and 100mM
L-glutamine. Murine E14 ES cells were cultured in Glasgow
Minimum Essential Medium (GMEM) supplemented with
10% fetal calf serum, 100 𝜇g/mL penicillin, 100 𝜇g/mL
streptomycin, 100mM L-glutamine, 100𝜇g/mL nonessential
amino acids (NEAAs), 10 𝜇g/mL 2-mercaptoethanol (2-ME),
and 10 𝜇g/mL leukemia inhibitory factor (LIF) (Sigma
L5158). Both cell types were cultured in T25 or T75 tissue
culture flasks in tissue incubators with 5% CO
2
at 37∘C.
4.2. siRNA. siRNA knockdown experiments of TET genes
were conducted using Dharmacon siGENOME siRNA
duplexes (Thermo Fisher Scientific Inc.) according to
the manufacturer’s instructions. siRNA molecules against
murine TET1 (Cxxc6 1) and TET2 (E130014J05Rik 5 and
E130014J05Rik 6) were obtained and the Dharmacon
siGENOME nontargeting siRNA number 2 (D-001210-02)
was used as a negative control. Knockdown experiments
were performed on E14 ES cells cultured in LIF-containing
medium on gelatin coated 12-well plates at a density of 1×105
cells per well. Serial siRNA transfections were performed
using 50 nM siRNA and Lipofectamine RNAiMAX reagent
(Invitrogen). Retransfectionswere performedonpreadherent
cells at day 2 at a split of 1 : 4 and finally at day 4 at a split of
1 : 2 in 6-well plates. Cells were harvested at day 5 for HPLC
mass spectrometry analyses.
4.3. HPLC Mass Spectrometry Analysis. To measure levels
of 5hmC and 5mC a high-performance liquid chromatog-
raphy (HPLC) mass spectrometry technique was used,
measuring levels of 5-hydroxymethyl-deoxycytidine (5hmdC)
and 5-methyl-deoxycytidine (5mdC), respectively. DNA was
extracted and digested using benzonase and alkaline phos-
phatase and a 5𝜇L sample used for analysis. The HPLC con-
figuration was as follows: Phenomenex Gemini C18 column
(150 × 2.0mm ID) with 3𝜇m size particle guard cartridge,
mobile phase A, 0.1% formic acid B, acetonitrile/0.1% formic
acid:
0–2mins 1% B,
2–7mins 1% to 40% B,
7–14m mins 1% B.
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The Applied Biosystems QTrap MS/MS detector config-
uration was as follows: orthogonal electrospray ion source,
with parent ion/product ion in the following ratios:
dG–268.1/152.1,
5mdC–242.1/126.2,
5ohmdC–258.2/142.2.
Source temperature was 450∘C and a spray voltage of 3 kV
was used. Collision gas pressure was 1.5mTorr. Data was then
graphed as a percentage of deoxyguanosine bases.
4.4. Immunocytochemistry. Cells were passaged into wells
of a 24-well plate at 3000 cells per well containing poly-L-
lysine (PLL) coverslips 24 hours prior to immunolabeling.
Cells were indirectly labelled using the standard procedure
by removing coverslips and washing in phosphate buffered
saline (PBS), fixing cells in 4% paraformaldehyde for 20 min-
utes, rewashing in PBS, and permeabilising cells in 0.4% Tri-
ton for 5 minutes before washing again in PBS.The following
antibodieswere used as per themanufacturer’s recommended
dilutions and instructions: TET2 protein was labelled with
TET2 rabbit IgG (S-13; Santa Cruz Biotechnology Inc.) with
Alexa488 goat anti-rabbit (Invitrogen) secondary antibody.
5
hmC was labelled with 5hmC rabbit (Active Motif) with
Alexa488 goat anti-rabbit secondary antibody. Coverslips
were rinsed again in PBS and then costained with 4󸀠,6-
diamidino-2-phenylindole (DAPI) for 5 minutes and then
rinsed again. DAPI acts as a nuclear identifying control.
Coverslips were placed on Citifluor AF1 mounting medium
on glass slides and sealed with nail varnish. Cells were visual-
ized under a DM5000B (Leica) fluorescence microscope and
images captured using an attached DPC300FX (Leica) digital
camera.
4.5. Dual Luciferase Reporter Assay. Dual Luciferase
Reporter Assay (Promega) was optimized and conducted
as per the manufacturer’s instructions, using 20 𝜇L of each
reagent for each individual reading at 24 hrs posttransfection.
Relative luminescence was measured with a GloMax 20/20
Luminometer on the Dual Glo setting and the ratio of Renilla
protein (from the pRL plasmid) to Firefly protein (from the
pGL3 plasmid) luminescence was graphed.
Methylation of theRenilla luciferase reporter plasmidwas
conducted using the SssI methylase (Promega M0226S) as
this provided optimal methylation when compared to other
methylases when testing comparative luminescence and also
with a BstUI restriction digest, which cuts DNA at sites of
unmethylated 5󸀠 . . .CGCG. . .3󸀠 (data not shown).
4.6. Stable Transfection and Differentiation. pCDNA3 and
TET2-pCDNA3 plasmid constructs were kindly donated
by Professor Olivier Barnard of INSERM, Institut Gustave
Roussy, Villejuif, France. E14 cells were cultured in gelatin
coated plates and transfected using the LipofectamineLTX
and PLUS reagents (Invitrogen) with the TET2-pCDNA3
plasmid, pCDNA3 control plasmid ormock transfected, each
in triplicate. Incorporation of plasmid DNA was selected
using 300𝜇gmL− Geneticin G418 selection antibiotic (Invit-
rogen) at 5 days posttransfection for 14 days, from which
point 100 𝜇gmL− G418 was used. After the 14-day selection
period no mock transfected colonies were apparent.
Myeloid differentiation was measured by colony forming
cell assay (CFC), conducted using MethoCult Growth Factor
H4034 (Stem Cell Technologies). 3 × 3 cm plates of both
TET2-pCDNA3 and pCDNA3 stable transfect cells were
grown with GF H4034, with control plates of the stably
transfected lines grown without GF H4034. At 22 days,
colonies were classified according to the MethoCult GF
H4034 protocol and photographed using a light microscope-
mounted Canon Powershot G5 with B-52 lens adapter and
Carl Zeiss 426126 digital camera adapter.
Alkaline phosphatase analysis of stably transfected differ-
entiating E14 cells by removal of LIF was conducted using
Alkaline Phosphatase Leukocyte kit (Sigma-Aldrich). Stably
transfected cells were plated onto gelatin coated 10 cm tissue
culture plates at 1000 cells per plate in triplicate. Media were
changed at 72 hours after plating that did not contain LIF.
Cells were stained 7 days after removal of LIF and each colony
given a leukocyte alkaline phosphatase activity (LAPA) score
according to the protocol. Reference LAPA score colonies
were photographed as above.
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